Advanced health biotechnologies in Thailand: redefining policy directions

Velasco, Román Pérez; Chaikledkaew, Usa; Myint, Chaw Yin; Khampang, Roongnapa; Tantivess, Sripen; Teerawattananon, Yot

doi:10.1186/1479-5876-11-1

Cited by 126 publications

(104 citation statements)

References 21 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Perceived fatigue may be variable both within (55) and between (56) days in people with MS. Of the most common measures from studies included in this meta-analysis, the MFIS asks “how much of a problem fatigue has caused them during the past month, including the day of testing” (15). The FSS is not anchored by a time period and instead asks for “agreement” with items regarding fatigue (14), although it is sometimes “based on the previous week” (57).…”

Section: Discussionmentioning

confidence: 99%

Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis

Loy

Taylor

Fling

et al. 2017

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Objective Perceived fatigue (i.e., subjective perception of reduced capacity) is one of the most common and disabling symptoms for people with multiple sclerosis (MS). Perceived fatigue may also be related to performance fatigability (i.e., decline in physical performance over time), although study findings have been inconsistent. Objective To locate all studies reporting the relationship between perceived fatigue and fatigability in people with MS, determine the population correlation, and examine moderating variables of the correlation size. Methods In accordance with PRISMA guidelines, systematic searches were completed in Medline, PsychInfo, Google Scholar, and the Cochrane Library for peer-reviewed articles published between March 1983 and August 2016. Included articles measured perceived fatigue and performance fatigability in people with MS and provided a correlation between measures. Moderator variables expected to influence the relationship were also coded. Searches located 19 studies of 848 people with MS and a random-effects model was used to pool correlations. Results The mean correlation between fatigue and fatigability was positive, “medium” in magnitude, and statistically significant, r = 0.31 (95% CI = 0.21, 0.42), p < .001. Despite moderate between-study heterogeneity (I2 = 46%) no statistically significant moderators were found, perhaps due to the small number of studies per moderator category. Conclusion There is a significant relationship between perceived fatigue and fatigability in MS, such that people reporting elevated fatigue also are highly fatigable. The size of the relationship is not large enough to suggest fatigue and fatigability are the same construct, and both should continue to be assessed independently.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis

Loy

Taylor

Fling

et al. 2017

Journal of Psychosomatic Research

View full text Add to dashboard Cite

show abstract

“…This overexpression is correlated with poor overall survival and lung metastasis-free survival in patients with invasive ductal carcinomas as well as reduced relapse-free survival in patients with ER+ breast cancer (14,16). ACKR3 overexpression has also been confirmed in 45% of esophageal squamous cell carcinomas (7) and 60% of LUSC with undetectable expression in adjacent normal lungs. In patients with lung cancer, this overexpression is correlated with advanced stage, lymphatic invasion and poor survival rates (17,18).…”

Section: Introductionmentioning

confidence: 95%

Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts

et al. 2016

View full text Add to dashboard Cite

The atypical chemokine receptor ACKR3 (formerly CXCR7), overexpressed in various cancers compared to normal tissues, plays a pivotal role in adhesion, angiogenesis, tumorigenesis, metastasis and tumor cell survival. ACKR3 modulates the tumor microenvironment and regulates tumor growth. The therapeutic potential of ACKR3 has also been demonstrated in various murine models of human cancer. Literature findings underscore the importance of ACKR3 in disease progression and suggest it as an important diagnostic maker for non-invasive imaging of ACKR3 overexpressing malignancies. There are currently no reports on direct receptor-specific detection of ACKR3 expression. Here we report the evaluation of a radiolabeled ACKR3-targeted monoclonal antibody (ACKR3-mAb) for the non-invasive in vivo nuclear imaging of ACKR3 expression in human breast, lung and esophageal squamous cell carcinoma cancer xenografts. Methods ACKR3 transcripts were extracted from Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA) and the Clinical Lung Cancer Genome Project (CLCGP). 89Zr-ACKR3-mAb was evaluated in vitro and subsequently in vivo by positron emission tomography (PET) and ex vivo biodistribution studies in mice xenografted with breast (MDA-MB-231-ACKR3 (231-AC-KR3), MDA-MB-231 (231), MCF7), lung (HCC95) or esophageal (KYSE520) cancer cells. In addition, ACKR3-mAb was radiolabeled with Iodine-125 and evaluated by single photon emission computed tomography (SPECT) imaging and ex vivo biodistribution studies. Results ACKR3 transcript levels were highest in lung squamous cell carcinoma (LUSC) among the 21 cancer type data extracted from TCGA. Also, CLCGP data showed that LUSC has the highest CXCR7 transcript levels compared to other lung cancer subtypes. The 89Zr-ACKR3-mAb was produced in 80±5% radiochemical yields with >98% radiochemical purity. In vitro cell uptake of 89Zr-ACKR3-mAb correlated with gradient levels of cell surface ACKR3 expression observed by flow cytometry. In vivo PET imaging and ex vivo biodistribution studies in mice with breast, lung and esophageal cancer xenografts consistently showed enhanced 89Zr-ACKR3-mAb uptake in high ACKR3 expressing tumors. SPECT imaging of 125I-ACKR3-mAb showed the versatility of ACKR3-mAb for in vivo monitoring of ACKR3 expression. Conclusions Data from this study suggest ACKR3 to be a viable diagnostic marker and demonstrate the utility of radiolabeled ACKR3-mAb for in vivo visualization of ACKR3 overexpressing malignancies.

show abstract

“…Patients whose tumors contain TLT may be better positioned to respond to this novel class of agents, since their tumors can support trafficking of TIL. Many features of the immune contexture in tumors are being investigated for their relationship to therapeutic response [9], and the findings of Di Caro, et al, support the inclusion of TLT as one of these features.…”

mentioning

confidence: 99%

“…Additionally, the current Immunoscore focuses on the host’s adaptive immune response to tumor, and does not include features of potential adaptive immune resistance by tumor, such as PD-L1 expression, which could protect tumors from immune destruction [8]. Other important practical considerations include how best to characterize the local immune milieu within tumors, i.e., with routine hematoxylin and eosin review of TIL grade [8, 12], by immunohistochemical analysis of immune cell subsets and presence of TLT [2,4,5], or molecularly using gene expression signatures [4,9]. Thresholds will have to be determined as well as standardized methods for quantification that translate across institutions.…”

mentioning

confidence: 99%